Table 9.
DBPR110-resistant variants remained fully sensitive to IFN-α, VX-950, and 2′CMA
| Amino acid substitution(s) | EC50 of the indicated inhibitora |
|||
|---|---|---|---|---|
| DBPR110 (pM) | IFN-α (IU/ml) | 2′CMA (nM) | VX-950 (nM) | |
| None (parental) | 1.5 ± 0.6 | 3.9 ± 0.3 | 33.7 ± 6.9 | 127.3 ± 17.6 |
| P58L | 564 ± 194 | 3.2 ± 1.2 | 27.7 ± 9.8 | 256.5 ± 70.4 |
| Y93N | 3,821 ± 1,677 | 3.1 ± 1.2 | 28.9 ± 1.3 | 158.1 ± 33.3 |
| Y93H | 1,408 ± 293 | 3.7 ± 1.9 | 29.2 ± 7.4 | 159.4 ± 21.8 |
| Y93N V153M M202L M265V | 27,326 ± 12,349 | 2.5 ± 1.4 | 24.2 ± 5.7 | 142.1 ± 6.2 |
| Y93H V153M M202L M265V | 8,736 ± 2,370 | 2.3 ± 1.2 | 24.1 ± 5.9 | 158.2 ± 66.8 |
a
Means ± standard deviations determined from transient transfection assays (n ≥ 3).